Daniel T. Starczynowski, PhD

Katherine Stewart Waters Endowed Chair of Hematologic Malignancies
Director, Advanced Leukemia Therapies and Research Center
Associate Director for Basic Sciences, UC Cancer Center
Institute Associate Director, Cancer and Blood Diseases Institute
Co-Chief Scientific Officer, Innovations Ventures
Co-Leader, Hematologic Malignancies Program
Member, Division of Experimental Hematology and Cancer Biology
Professor, UC Department of Pediatrics

daniel.starczynowski@cchmc.org

About

Biography

Daniel T. Starczynowski, PhD, received his PhD in molecular biology from Boston University. He studied the NF-kB family of transcription factors and their role in B-cell lymphomas. During his postdoctoral fellowship at the BC Cancer Research Center, Dr. Starczynowski identified and characterized novel candidate genes in myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML).

Following his postdoctoral training, Dr. Starczynowski joined the faculty at Cincinnati Children’s Hospital Medical Center and at the University of Cincinnati as an Assistant Professor. Dr. Starczynowski’s laboratory investigates the molecular and cellular basis of hematologic malignancies with the goal to advance novel therapeutic strategies.

BS: Fairleigh Dickinson University, Teaneck, NJ, 2000.

PhD: Boston University, Boston, MA, 2006.

Postdoctoral Fellow: University of British Columbia/BC Cancer Research Centre, Vancouver, Canada, 2010.

Services and Specialties

Research Areas

Publications

Characterization of E1 enzyme dependencies in mutant-UBA1 human cells reveals UBA6 as a novel therapeutic target in VEXAS syndrome. Clough, CA; Cunningham, C; Philbrook, SY; Hueneman, KM; Sampson, AM; Choi, K; Greis, KD; Starczynowski, D. Leukemia. 2025; 39:1997-2009.

Microbial metabolite drives ageing-related clonal haematopoiesis via ALPK1. Agarwal, P; Sampson, A; Hueneman, K; Choi, K; Jakobsen, NA; Uible, E; Ishikawa, C; Yeung, J; Bolanos, L; Zhao, X; Galloway-Pena, J; Byrd, JC; Vyas, P; Starczynowski, DT. Nature. 2025; 642:201-211.

The IRAK4 long isoform as widely upregulated in non-splicesome mutated acute myeloid leukemia and as altered by hypomethylating agent therapy. Vick, EJ; Walulik, S; Sampson, A; Hassan, A; Wunderlich, M; Volk, A; Starczynowski, D. Journal of Clinical Oncology. 2025; 43:6524.

Ubiquitin-conjugating enzyme UBE2N modulates proteostasis in immunoproteasome-positive acute myeloid leukemia. Ishikawa, C; Barreyro, L; Sampson, AM; Hueneman, KM; Choi, K; Philbrook, SY; Choi, I; Bolanos, LC; Wunderlich, M; Volk, AG; Watowich, SS; Greis, KD; Starczynowski, DT. The Journal of Clinical Investigation. 2025; 135:e184665.

IRAK1/4/pan-FLT3 Kinase Inhibitors with Reduced hERG Block as Treatments for Acute Myeloid Leukemia. Hoyt, SB; Finocchio, CJ; Croll, E; Tawa, GJ; Zhang, M; Wang, J; Li, H; Ma, L; Li, K; Zhang, X; Culver-Cochran, AE; Rosenbaum, JS; Starczynowski, DT; Thomas, CJ. ACS Medicinal Chemistry Letters. 2025; 16:887-895.

Splicing regulatory dynamics for precision analysis and treatment of heterogeneous leukemias. Venkatasubramanian, M; Schwartz, L; Ramachandra, N; Bennett, J; Subramanian, KR; Chen, X; Gordon-Mitchell, S; Fromowitz, A; Pradhan, K; Shechter, D; Grimes, HL; Starczynowski, DT; Verma, A; Salomonis, N. Science Translational Medicine. 2025; 17:eadr1471.

Abstract 5480: Live cell real-time quantification of drug-target engagement for rapid drug discovery. Babic, I; Bryan, N; Cunningham, C; Sampson, A; Starczynowski, D; Nurmemmedov, E. Cancer Research. 2025; 85:5480.

Reducing clinical trial eligibility barriers for patients with MDS: an icMDS position statement. Borate, U; Pugh, K; Waller, A; Welkie, RL; Huang, Y; Bewersdorf, JP; Stahl, M; DeZern, AE; Platzbecker, U; Sekeres, MA; Bennett, JM; List, AF; Brunner, AM; Zeidan, AM. Blood. 2025; 145:1369-1381.

TIFAB modulates metabolic pathways in KMT2A::MLLT3-induced AML through HNF4A. Wang, Y; Xiu, Y; Dong, Q; Zhao, J; Neumbo, K; Miyagi, M; Borcherding, N; Fu, L; De Celis, H; Pintozzi, N; Starczynowski, DT; Zhao, C. Blood Advances. 2025; 9:844-855.

Smoking-Associated Carcinogen-Induced Inflammation Promotes Lung Carcinogenesis via IRAK4 Activation. Aggarwal, RK; Sidoli, S; Wang, J; Sahu, S; Sanawar, R; Gupta, V; Aluri, S; Sukrithan, V; Vegivinti, CT R; Zavras, PD; LaFave, LM; Cheng, H; Verma, A; Zou, Y. Clinical Cancer Research. 2025; 31:746-755.